DK2943189T3 - Mitoguazon til behandling af progressiv multipel sklerose - Google Patents

Mitoguazon til behandling af progressiv multipel sklerose Download PDF

Info

Publication number
DK2943189T3
DK2943189T3 DK14737914.3T DK14737914T DK2943189T3 DK 2943189 T3 DK2943189 T3 DK 2943189T3 DK 14737914 T DK14737914 T DK 14737914T DK 2943189 T3 DK2943189 T3 DK 2943189T3
Authority
DK
Denmark
Prior art keywords
mitoguazone
treatment
multiple sclerosis
progressive multiple
progressive
Prior art date
Application number
DK14737914.3T
Other languages
Danish (da)
English (en)
Inventor
Jeremy Blitzer
John Mckearn
Original Assignee
Pathologica Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pathologica Llc filed Critical Pathologica Llc
Application granted granted Critical
Publication of DK2943189T3 publication Critical patent/DK2943189T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
DK14737914.3T 2013-01-08 2014-01-08 Mitoguazon til behandling af progressiv multipel sklerose DK2943189T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361750336P 2013-01-08 2013-01-08
US201361823276P 2013-05-14 2013-05-14
PCT/US2014/010714 WO2014110154A1 (en) 2013-01-08 2014-01-08 Methods and comp0stions for treatment of demyelinating diseases

Publications (1)

Publication Number Publication Date
DK2943189T3 true DK2943189T3 (da) 2021-04-06

Family

ID=51167347

Family Applications (1)

Application Number Title Priority Date Filing Date
DK14737914.3T DK2943189T3 (da) 2013-01-08 2014-01-08 Mitoguazon til behandling af progressiv multipel sklerose

Country Status (11)

Country Link
US (2) US10085955B2 (cg-RX-API-DMAC7.html)
EP (2) EP3831372A1 (cg-RX-API-DMAC7.html)
JP (2) JP6370804B2 (cg-RX-API-DMAC7.html)
CN (2) CN105163730B (cg-RX-API-DMAC7.html)
AU (2) AU2014205529B2 (cg-RX-API-DMAC7.html)
BR (1) BR112015016189A8 (cg-RX-API-DMAC7.html)
CA (1) CA2896977C (cg-RX-API-DMAC7.html)
DK (1) DK2943189T3 (cg-RX-API-DMAC7.html)
ES (1) ES2859553T3 (cg-RX-API-DMAC7.html)
IL (1) IL239851B (cg-RX-API-DMAC7.html)
WO (1) WO2014110154A1 (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008112659A2 (en) 2007-03-09 2008-09-18 Pathologica Llc Regulation of osteopontin
US9675566B2 (en) 2009-07-16 2017-06-13 Pathologica Llc Method of treatment with anti-inflammatory and analgesic compounds which are GI-, renal-, and platelet-sparing
NZ597488A (en) 2009-07-16 2014-10-31 Pathologica Llc Pharmaceutical for oral delivery comprising mgbg and methods of treating disease
WO2012100043A2 (en) 2011-01-19 2012-07-26 Pathlogica LLC Controlled release oral pharmaceutical dosage forms comprising mgbg
WO2014110154A1 (en) 2013-01-08 2014-07-17 Pathologica Llc Methods and comp0stions for treatment of demyelinating diseases
US20160058730A1 (en) * 2014-08-29 2016-03-03 Cadila Healthcare Limited Pharmaceutical compositions of teriflunomide
MA41785A (fr) 2015-03-20 2018-01-23 Biogen Ma Inc Procédés et compositions pour l'administration intraveineuse de fumarates pour le traitement de maladies neurologiques
EP3118621A1 (en) * 2015-07-14 2017-01-18 Fundació Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) Methods and compositions for the diagnosis and for the treatment of adrenoleukodystrophy
EP3347017A1 (en) * 2015-09-08 2018-07-18 Georg-August-Universitaet Goettingen Stiftung Oeffentlichen Rechts, Universitaetsmedizin Quinoline derivates for use in treating leukodystrophy and treatment method
CN108883077A (zh) * 2016-03-07 2018-11-23 国立大学法人大阪大学 神经损伤治疗用药剂缓释片材
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
JP7193448B2 (ja) 2016-08-31 2022-12-20 マピ ファーマ リミテッド 酢酸グラチラマーを含むデポシステム
IL316573A (en) 2017-03-26 2024-12-01 Mapi Pharma Ltd Storage systems containing glatiramer acetate for the treatment of multiple sclerosis
SG11202010087UA (en) * 2018-04-13 2020-11-27 Mordechai Chevion Compositions and methods for treatment of demyelination
IL293469B2 (en) * 2019-12-19 2024-04-01 Active Biotech Ab Compounds for treatment of eye diseases associated with excessive vascularisation

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4201788A (en) 1976-10-20 1980-05-06 University Patents, Inc. Process for alleviating proliferative skin diseases
US5614557A (en) 1977-07-11 1997-03-25 Marion Merrell Et Compagnie C/O Merrell Pharmaceuticals Inc. Method of controlling tumor growth rate
US4520031A (en) 1981-06-01 1985-05-28 The United States Of America As Represented By The Secretary Of Department Of Health And Human Services Method for reducing toxic effects of methyl-glyoxal bis-guanylhydrazone
US5639600A (en) 1994-08-05 1997-06-17 The Regents Of The University Of California Diagnosis and treatment of cell proliferative disease having clonal macrophage involvement
US5580715A (en) 1994-08-05 1996-12-03 The Regents Of The University Of California Diagnosis of cancer having clonal macrophage involvement
US5698563A (en) 1995-01-13 1997-12-16 Alteon Inc. Bis- hydrazones!
EP1459744A3 (en) 1996-09-13 2004-12-15 University Of Florida Research Foundation, Inc. Method of inhibiting biosynthesis of elf5a
AR009380A1 (es) 1996-10-21 2000-04-12 Sumitomo Chemical Co Proceso de preparacion de un derivado de piridazin-3-ona, util como herbicida, acido carboxilico de utilizacion en el mismo, sal de este ultimo y proceso para preparar dicho acido carboxilico
US6083496A (en) 1996-10-22 2000-07-04 Universite Laval Polyamine transport inhibitors
AU758570B2 (en) 1997-07-15 2003-03-27 Mediquest Therapeutics, Inc. Novel polyamine analogues as therapeutic and diagnostic agents
US5889061A (en) 1997-10-15 1999-03-30 Wisconsin Alumni Research Foundation Conformationally restricted polyamines
US7087648B1 (en) 1997-10-27 2006-08-08 The Regents Of The University Of California Methods for modulating macrophage proliferation using polyamine analogs
US8198334B2 (en) 1997-10-27 2012-06-12 Pathologica Llc Methods for modulating macrophage proliferation in ocular disease using polyamine analogs
US6169115B1 (en) 1998-05-22 2001-01-02 Rima Kaddurah-Daouk Use of aminoguanidine analogs for the treatment of diseases of the nervous system
MXPA01011000A (es) 1999-04-30 2003-06-30 Slil Biomedical Corp Analogos de poliaminas conformacionalmente restringidos como terapias para enfermedades.
US6544541B1 (en) 1999-06-02 2003-04-08 Cardiovascular Solutions, Inc. Devices and compounds for treating arterial restenosis
MXPA02008023A (es) * 2000-02-18 2005-06-30 Yeda Res & Dev Formulaciones de copolimero 1 para dosificacion oral, nasal y pulmonar.
JP2004513136A (ja) 2000-11-08 2004-04-30 スリル　バイオメディカル　コーポレーション 抗癌剤として有用な新規ポリアミンアナログ−アミノ酸結合体
US7754765B2 (en) 2000-12-01 2010-07-13 Radical Vision Therapeutics Inc Copper chelators for treating ocular inflammation
CA2433807C (en) 2001-01-08 2012-04-24 Oridigm Corporation Hydrophobic polyamine analogs and methods for their use
WO2003013609A1 (fr) 2001-08-03 2003-02-20 Takeda Chemical Industries, Ltd. Medicaments a liberation continue
US7045550B2 (en) 2001-08-07 2006-05-16 Wisconsin Alumni Research Foundation Polyamines and analogs for protecting cells during cancer chemotherapy and radiotherapy
CA2454879A1 (en) 2001-08-15 2003-02-27 The Regents Of The University Of California Retrovirus isolated from mantle histiocytes in mantle cell lymphoma
US7273888B2 (en) 2001-11-16 2007-09-25 Als Therapy Development Foundation, Inc. Use of difluoromethylornithine (DFMO) for the treatment of amyotrophic lateral sclerosis
US7282490B2 (en) * 2001-11-21 2007-10-16 The Board Of Trustees Of The Leland Stanford Junior University Osteopontin-related compositions and methods
US7622117B2 (en) 2002-04-17 2009-11-24 Dynamis Therapeutics, Inc. 3-deoxyglucosone and skin
EP1389480A1 (en) 2002-08-14 2004-02-18 Mondobiotech Interferon SA Therapeutical use of guanylhydrazones for the inhibition of CD83 dependent processes and dendritic cell maturation
WO2004069174A2 (en) 2003-01-31 2004-08-19 Slil Biomedical Corporation Monitoring and treatment of amyotrophic lateral sclerosis
ITMI20040682A1 (it) 2003-04-08 2004-07-06 Mitsubishi Pharma Corp Composti organici
RU2375048C2 (ru) 2003-07-17 2009-12-10 Д-Р Редди'С Лабораторис Инк. Фармацевтическая композиция с набухающим покрытием
US20050025825A1 (en) 2003-07-31 2005-02-03 Xanodyne Pharmacal, Inc. Tranexamic acid formulations with reduced adverse effects
WO2005041988A1 (en) 2003-10-22 2005-05-12 University Of Florida Method and composition for pain amelioration
AU2004319105A1 (en) 2004-03-29 2005-11-10 Mediquest Therapeutics, Inc. Polyamine analogs that activate antizyme frameshifting
US7445794B1 (en) 2004-04-29 2008-11-04 The Regents Of The University Of Colorado Methods for treating human proliferative diseases, with a combination of fatty acid metabolism inhibitors and glycolytic inhibitors
AU2006209225A1 (en) * 2005-01-28 2006-08-03 Xanthus Pharmaceuticals, Inc. Compounds for treating inflammatory and demyelinating diseases
EP1916995B2 (en) 2005-07-29 2022-06-29 Stichting Groningen Centre for Drug Research Ph-controlled pulsatile delivery system, methods for preparation and use thereof
US8912214B2 (en) 2005-07-29 2014-12-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of Chk2 kinase inhibitors for cancer treatment
AU2006292063B2 (en) 2005-09-23 2012-12-06 Pathologica, Llc. Methods for treating viral infections using polyamine analogs
WO2007040535A1 (en) 2005-10-03 2007-04-12 Cellgate, Inc. Use of polyamine analogs for treatment and prevention of intestinal polyps
US20110091418A1 (en) 2006-09-25 2011-04-21 Pathlogica, LLC Methods for treating viral infections using polyamine analogs
JP4929505B2 (ja) 2006-10-31 2012-05-09 Ｉｄｅｃ株式会社 リレーソケット
US8092648B2 (en) 2007-03-09 2012-01-10 Kayren Joy Nunn Regenerated cotton board material and method of manufacture
WO2008112659A2 (en) * 2007-03-09 2008-09-18 Pathologica Llc Regulation of osteopontin
WO2008112251A1 (en) 2007-03-14 2008-09-18 Progen Pharmaceuticals, Inc. Cyclopropyl-containing polyamine analogs as disease therapies
WO2009018368A1 (en) 2007-07-30 2009-02-05 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Combination treatment of nmda (n-methyl-d-aspartate)-enhancer, glycine transporter inhibitor, d-amino acid oxidase inhibitor (daaoi) for neuropsychiatric disorders
EP2337795A2 (en) * 2008-10-01 2011-06-29 Dako Denmark A/S Mhc multimers in cancer vaccines and immune monitoring
WO2010045265A1 (en) 2008-10-13 2010-04-22 Biovista, Inc. Compositions and methods for treating multiple sclerosis
JP2012511519A (ja) 2008-12-10 2012-05-24 アンフイ ジョンレン テクノロジー コーポレイション，リミテッド 制御放出組成物
US20100189791A1 (en) 2009-01-23 2010-07-29 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline malate formulation
US9675566B2 (en) 2009-07-16 2017-06-13 Pathologica Llc Method of treatment with anti-inflammatory and analgesic compounds which are GI-, renal-, and platelet-sparing
NZ597488A (en) 2009-07-16 2014-10-31 Pathologica Llc Pharmaceutical for oral delivery comprising mgbg and methods of treating disease
EP2283830A1 (en) 2009-07-23 2011-02-16 Actogenix N.V. Aqueous enteric capsule coating
EP2343075A1 (en) * 2010-01-04 2011-07-13 Neurotec Pharma, S.L. Diazoxide for use in the treatment a central nervous system (CNS) autoimmune demyelinating disease
TWI590821B (zh) 2011-01-18 2017-07-11 輝瑞有限公司 固體分子分散液
WO2012100043A2 (en) 2011-01-19 2012-07-26 Pathlogica LLC Controlled release oral pharmaceutical dosage forms comprising mgbg
JP6133790B2 (ja) * 2011-02-18 2017-05-24 ザ スクリプス リサーチ インスティテュート ミエリン形成細胞運命へのオリゴデンドロサイト前駆細胞の定方向分化
WO2014110154A1 (en) 2013-01-08 2014-07-17 Pathologica Llc Methods and comp0stions for treatment of demyelinating diseases

Also Published As

Publication number Publication date
CN105163730B (zh) 2018-10-30
AU2014205529A1 (en) 2015-07-09
EP3831372A1 (en) 2021-06-09
BR112015016189A2 (pt) 2017-07-11
US10085955B2 (en) 2018-10-02
AU2014205529B2 (en) 2018-08-09
AU2018247351A1 (en) 2018-11-08
ES2859553T3 (es) 2021-10-04
IL239851A0 (en) 2015-08-31
JP2016504389A (ja) 2016-02-12
US20150359761A1 (en) 2015-12-17
CN105163730A (zh) 2015-12-16
BR112015016189A8 (pt) 2019-10-22
US10350178B2 (en) 2019-07-16
CA2896977A1 (en) 2014-07-17
EP2943189A4 (en) 2016-07-06
JP6370804B2 (ja) 2018-08-08
JP2018172427A (ja) 2018-11-08
US20180360783A1 (en) 2018-12-20
IL239851B (en) 2020-07-30
EP2943189A1 (en) 2015-11-18
HK1217451A1 (en) 2017-01-13
NZ709157A (en) 2020-09-25
CA2896977C (en) 2021-12-07
WO2014110154A1 (en) 2014-07-17
NZ749754A (en) 2020-09-25
CN109432073A (zh) 2019-03-08
EP2943189B1 (en) 2021-03-10
AU2018247351B2 (en) 2020-04-09

Similar Documents

Publication Publication Date Title
DK2943189T3 (da) Mitoguazon til behandling af progressiv multipel sklerose
DK2983787T3 (da) Fremgangsmåde til behandling af posttraumatisk stresssygdom
DK3076967T3 (da) Fremgangsmåder til behandling af residuelle symptomer på skizofreni
DK2994159T3 (da) Forudsigelse af t-celleepitopers immunogenicitet
EP2982689A4 (en) FC-REGIONS-VARIATIONS
DK2968208T3 (da) Behandling af kataplexi
DK3080100T3 (da) Hæmmere af lysinspecifik demethylase-1
DK2964315T3 (da) System til behandling af neuromotorisk dysfunktion
DK3811943T3 (da) Forbindelse til anvendelse til behandling af øjenlidelser
PL3427584T3 (pl) Sposób zwalczania rdzy
DK2981255T3 (da) Terapeutiske anvendelser af empagliflozin
DK3062811T3 (da) Angiopoietin-baserede interventioner til behandling af cerebral malaria
DK2976359T4 (da) Fremgangsmåder til behandling af osteogenesis imperfecta
PT2953948T (pt) Antagonistas de integrina fluorada
DK3010895T3 (da) Fremgangsmåde til fremstilling af 4-propargyleret aminobenzoxazinoner
DK2836460T3 (da) Fremgangsmåde til fremstilling af graphen
DK3021839T3 (da) Sammensætninger for behandling af fibrose
EP2982674A4 (en) PYRIDINYLPYRAZOLOCHINOLINVERBINDUNG
DK3003366T3 (da) På hinanden følgende overlappende peptider til behandling af allergi overfor husstøvmider
DK3065790T3 (da) Fremgangsmåder til fjernelse af alpha-galactose
EP2945942A4 (en) Voriconazole IMMUNOASSAY
DK2777689T3 (da) Ny farmaceutisk sammensætning til behandling af svampeinfektioner
DK2964381T3 (da) Sammensætning til fremstilling af silikonegummimasser
ITUA20161318A1 (it) Assieme di componenti elettrici di bicicletta
IL243179B (en) Dendritic cell asgpr targeting immunotherapeutics for multiple sclerosis